Roche gets a leg up in the an­ti-TIG­IT race with first break­through des­ig­na­tion for PhII win­ner tiragolum­ab

In the race to ush­er in a next gen­er­a­tion of im­munother­a­pies, Roche’s Genen­tech has emerged from the pack, nab­bing the first break­through des­ig­na­tion for an …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER